Inoscorpi^TM MENA is composed of equine derived antibodies or immunoglobulin fragments F(ab’)₂, which have been raised against the venoms of medically relevant scorpion species of the MENA region.

Overall, with 10 species, Inoscorpi^TM MENA provides a large coverage of medically relevant scorpion species in MENA region.

• Inosan Biopharma antivenoms are polyvalent and cover most species that are medically relevant for a given region. Venoms used for the immunization process come from species representative of the regions the antivenoms are intended for.
• Inosan antivenoms are made of highly specific F(ab’)₂ ⁽¹⁾, meaning that there is a high proportion of effective F(ab’)₂capable to specifically bind to the toxic components of the venoms and neutralize them. Thanks to its high specificity, Inosan antivenoms can include more species in one vial with less proteins.
• Inosan Biopharma antivenoms are highly purified with F(ab’)₂ level reaching 95%⁽¹⁾. They have a low protein level (<10%, no more than 100 mg of protein per mL in the resuspended product) and are preservatives free.

The clinical efficacy profile of Inoscorpi™ MENA has not been evaluated in a dedicated clinical study so far. By neutralizing the toxic components of scorpion venom, Inoscorpi^TM MENA has the ability to rapidly control envenomation signs which may include local pain, fever, digestive disorders (nausea, vomiting, abdominal bloating, diarrhea), neurological disorders (somnolence, agitation, fasciculation of the stung limb, hypersalivation, convulsion, coma), cholinergic syndrome (vomiting, salivation, heavy sweating, tearing, miosis, priapism, bronchial disease, bradycardia), adrenergic storm (tachycardia, peripheral vasoconstriction, arterial hypertension, mydriasis), cardiac disorders and respiratory disorders.

The clinical safety profile of Inoscorpi^TM MENA has not been evaluated in a dedicated clinical study so far. The administration of equine origin F(ab´)₂ fragments may be associated with allergic reactions including sweating, nausea, rashes, modest fall in blood pressure; these reactions are generally of mild intensity. Anaphylactoid reactions with hypertension, dyspnea, urticaria, Quincke’s edema or severe allergic shock may also occur. However, the actual generalized allergic shock only appears in an exceptional manner. In this case it is recommended to immediately suspend the infusion and to administer corticosteroids, diphenhydramine hydrochloride, as well as any therapy that the healthcare provider deems appropriate. Similar reactions to serum sickness have been described after the administration of origin proteins that may appear roughly 6 days after treatment onset. The clinical signs are fever, pruritus, erythema or urticaria, adenopathy and arthralgias. However, these types of reactions are observed in less than 1% of the patients who are given equine origin F(ab´)₂ fragments.

Inoscorpi^TM MENA should be administered intravenously through slow direct injection or infusion. It is recommended to evaluate the patient every 2 hours after the initial administration and to renew administration (1 vial) as long as symptoms persist or are getting worse. A larger number of vials might be administered depending on the severity of the envenomation and the general condition of the patient.

Due to the fatal risk associated with envenomation, the antivenom may be dispensed in the specific population of patients allergic to equine origin proteins, provided that treatment for anaphylactic shock can be implemented immediately.

Envenomation in children generally leads to more severe symptoms and a higher rate of lethality and sequelae. This is due to their small body weight and volume that lead to a lower dilution of venom.

Inosan Biopharma antivenoms are lyophilized, this makes the management of the antivenom very convenient and inexpensive compared to liquid presentations, particularly in tropical regions.

Inosan Biopharma maintains GMP certification at all times from COFEPRIS, the Mexican agency, recognized by the WHO, for the qualification of manufacturers of vaccines and biological products. In addition, Inosan follows the guidelines for the manufacturing of antivenom products established by the WHO.